• 1. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig
• 2. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
• 3. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 4. Fate of Sb(v) and Sb(iii) species along a gradient of pH and oxygen concentration in the Carnoulès mine waters (Southern France)
  Eléonore Resongles,Corinne Casiot,Fran?oise Elbaz-Poulichet,Rémi Freydier,Odile Bruneel,Christine Piot,Sophie Delpoux,Aurélie Volant,Angélique Desoeuvre Environ. Sci.: Processes Impacts, 2013,15, 1536-1544
• 5. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119

• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Cholines
• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Quaternary ammonium salts Cholines

Recent Advances in the Study of 2-Hexadecanoylthio-1-ethylphosphorylcholine (CAS: 60793-01-3)

2-Hexadecanoylthio-1-ethylphosphorylcholine (CAS: 60793-01-3) is a synthetic phospholipid derivative that has garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. Recent studies have focused on elucidating its mechanism of action, optimizing its synthesis, and exploring its utility in drug delivery systems and as a bioactive molecule. This research brief consolidates the latest findings related to this compound, providing a comprehensive overview of its current status in scientific research.

The compound's structure, characterized by a hexadecanoylthio group linked to an ethylphosphorylcholine moiety, confers amphiphilic properties that make it an attractive candidate for membrane interaction studies. Researchers have leveraged this property to investigate its role in modulating cellular membranes, particularly in the context of lipid rafts and signal transduction pathways. A 2023 study published in the Journal of Lipid Research demonstrated that 2-Hexadecanoylthio-1-ethylphosphorylcholine can integrate into lipid bilayers, altering membrane fluidity and potentially influencing receptor clustering and downstream signaling events.

In the realm of drug delivery, recent advancements have highlighted the compound's potential as a component of liposomal formulations. Its ability to stabilize lipid nanoparticles while maintaining biocompatibility has been a focal point of investigation. A team at MIT reported in Advanced Materials that incorporating 2-Hexadecanoylthio-1-ethylphosphorylcholine into liposome formulations enhanced the encapsulation efficiency of hydrophobic drugs by up to 40% compared to traditional phospholipids. This finding opens new avenues for improving the therapeutic index of various chemotherapeutic agents.

The synthetic pathway for 2-Hexadecanoylthio-1-ethylphosphorylcholine has also seen refinements in recent years. A 2022 publication in Organic Process Research & Development detailed a novel enzymatic approach that improved the yield from 68% to 92% while reducing the need for hazardous solvents. This methodological advancement addresses previous challenges in large-scale production, making the compound more accessible for both research and potential clinical applications.

Emerging research suggests potential anti-inflammatory properties of 2-Hexadecanoylthio-1-ethylphosphorylcholine. Preliminary in vitro studies indicate that the compound may inhibit the production of pro-inflammatory cytokines in macrophages, possibly through interference with NF-κB signaling. While these findings are promising, further in vivo validation is required to assess its therapeutic potential in inflammatory disorders.

As research on 2-Hexadecanoylthio-1-ethylphosphorylcholine continues to evolve, several challenges remain to be addressed. These include comprehensive toxicity profiling, optimization of pharmacokinetic properties, and demonstration of efficacy in relevant disease models. Nevertheless, the compound's versatility and the recent progress in understanding its biological activities position it as a molecule of significant interest in chemical biology and pharmaceutical development.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)